Delving into the Latest Updates on KRAS G12D inhibitors (Curve Therapeutics) with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms-

Target

KRAS G12D

Mechanism

KRAS G12D inhibitors(GTPase KRas G12D inhibitors)

Therapeutic Areas

Neoplasms

Active Indication

Neoplasms

Inactive Indication-

Originator Organization

Curve Therapeutics Ltd.

Active Organization

Curve Therapeutics Ltd.

Inactive Organization-

Drug Highest PhaseDiscovery

First Approval Date-

Regulation-

NSCLC has a diverse genomic background with mutations in key proto-oncogenic drivers including Kirsten rat sarcoma (KRAS) and epidermal growth factor receptor (EGFR). Roughly 40% of adenocarcinoma harbor Kras activating mutations regardless of smoking history. Most KRAS mutations are located at G12, which include G12C (roughly 40%), G12V (roughly 20%), and G12D (roughly 15%). KRAS mutated NSCLC have higher tumor mutational burden and some have increased PD-1 expression, which has resulted in better responses to immunotherapy than other oncogenes. While initial treatment for metastatic NSCLC still relies on chemo-immunotherapy, directly targeting KRAS has proven to be efficacious in treating patients with KRAS mutated metastatic NSCLC. To date, two G12C inhibitors have been FDA-approved, namely sotorasib and adagrasib. In this review, we summarize the different drug combinations used to target KRAS G12c, upcoming G12D inhibitors and novel therapies targeting KRAS.

100 Deals associated with KRAS G12D inhibitors (Curve Therapeutics)

Login to view more data